Compare CNSY & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNSY | LRE |
|---|---|---|
| Founded | 1996 | 2001 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 17.9M |
| IPO Year | 2016 | 2022 |
| Metric | CNSY | LRE |
|---|---|---|
| Price | $1.69 | $1.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $27.75 | N/A |
| AVG Volume (30 Days) | ★ 166.5K | 16.9K |
| Earning Date | 10-29-2026 | 07-30-2015 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,213,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $414.61 | N/A |
| P/E Ratio | ★ N/A | $3.16 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.49 | $1.00 |
| 52 Week High | $4.03 | $1.86 |
| Indicator | CNSY | LRE |
|---|---|---|
| Relative Strength Index (RSI) | 34.47 | 48.85 |
| Support Level | $1.49 | N/A |
| Resistance Level | $1.96 | $1.35 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 27.68 | 93.33 |
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.